Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
Ductal carcinoma in situ (DCIS) is a significant challenge in the field of breast cancer management, representing a complex and nuanced condition that has undergone increased scrutiny in recent years. At Alfa Cytology, our team of experienced biologists work with you to develop DCIS therapeutics.
DCIS is a non-invasive form of breast cancer, where abnormal cells have been detected within the milk ducts of the breast, but have not yet penetrated the surrounding tissue. With the increased detection capabilities of modern screening techniques, DCIS now accounts for 20-25% of all breast cancer cases.
Fig.1 Progression of ductal carcinoma in situ to invasive breast cancer. (Van Seijen M., et al. 2019)
The primary goal of DCIS treatment is to prevent the development of invasive breast cancer, which can have more severe consequences. Without pr oper intervention, a significant proportion of DCIS lesions will progress to become invasive, increasing the risk of metastatic spread and potentially life-threatening outcomes. By implementing appropriate treatment strategies, such as surgery, radiation therapy, or targeted therapies, healthcare providers can effectively reduce the likelihood of DCIS progression.
| Therapeutics | Types | NCT | Phase |
| Anastrozole | Chemoprevention | NCT00256217 | |
| Pembrolizumab + Intralesional mRNA 2752 | Immunotherapy | NCT02872025 | |
| H2NVAC | Vaccine | NCT04144023 | |
| HER-2 Pulsed Dendritic cell Vaccine | NCT02061332 |
At Alfa Cytology, we are committed to advancing the field of DCIS research and translating cutting-edge scientific discoveries into tangible clinical benefits. Our comprehensive suite of services encompasses the full spectrum of preclinical research, from target identification and validation to the evaluation of novel therapeutic strategies.
We provide one-stop solutions for DCIS, including but not limited to the following.
Therapeutics Development
Modeling Services
Preclinical Research
Diagnostic Development
Through rigorous research and collaboration with experts in the field, we aim to identify novel therapeutic targets and develop innovative drugs that can effectively treat DCIS while minimizing side effects. Our company's expertise in drug development, including preclinical research and model development, allows us to accelerate pharmaceutical companies' research and development.
|
DCIS Cell Lines |
In Vitro 3D Models |
Animal Models |
HER2-Negative DCIS Cell Lines
HER2-Positive DCIS Cell Lines
|
|
|
We are committed to collaborating with healthcare providers and researchers to drive meaningful progress in this critical area of breast cancer management. By collaborating with Alfa Cytology, clients gain access to a comprehensive suite of services tailored to the unique needs of ductal carcinoma in situ research and therapeutic development. If you are interested in our service, please contact us.
Reference
